Last updated: August 14, 2025 | Contact: PrediX@FINOSOFT.ca | Affiliation: FinoSoft Technologies
Regulatory Notice: PrediX is intended for investigational/clinical evaluation use only and is not for primary diagnosis unless and until licensed by the relevant authorities. Statements below describe current capabilities and planned processes and should not be interpreted as regulatory claims
Canada Class II Medical Device licensing:
PrediX pursuing Health Canada Class II Medical Device licensing
Submission within 6 months
Expected approval 6–9 months
Disclaimer : “PrediX is currently available under pilot/evaluation agreements. Not yet approved for clinical use.”
Security & Compliance
At a glance
Data residency in Canada (cloud regions Montréal/Toronto)
Encryption: TLS 1.2+ in transit; AES‑256 at rest
Access: SSO (SAML/OIDC), MFA, RBAC (least privilege)
Audit: Immutable logs for access and admin actions
Standards: PIPEDA/PHIPA-aligned practices, DPAs/IMAs as required
Options: Managed cloud, customer VPC, or on‑premises
Policies & documentation
Security whitepaper, data flow diagrams, and subprocessors list are available under NDA.